Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organogenesis Holdings Inc.

www.organogenesis.com

Latest From Organogenesis Holdings Inc.

Budget Bill Makes End Run Around Medicare Payment Policy For Omidria, Amyvid

Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.

Medicare Policy

Device/Diagnostics Quarterly Deal-Making Statistics, Q2 2017

Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.

Medical Device In Vitro Diagnostics

M&A Analysis: No Spring For March Mergers

M&A deal activity waned in March, with a total of 9 deals completed in the month, down from 12 in February and 17 in March 2016. This third month brought the total number of deals for Q1 2017 to 33, a significant year-on-year decline compared to 51 in the first quarter of 2016.

M & A Deals

Market Intel: Intense Competition, Innovation Drive Healing Trends In Wound Care

The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.

Wound Healing & Tissue Repair Wound Management
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Organogenesis Holdings Inc.
  • Senior Management
  • Gary S Gillheeny, Sr., Pres. & CEO
    Timothy M Cunningham, CFO
    Brian Grow, Chief Commercial Officer
    Patrick Bilbo, COO
    Howard Walthall, EVP, Strategy & Mkt. Dev.
  • Contact Info
  • Organogenesis Holdings Inc.
    Phone: (781) 575-0775
    85 Dan Rd.
    Canton, MA 02021
    USA
UsernamePublicRestriction

Register